|Title||Gabapentin adjunctive therapy in neuropathic pain states.|
|Publication Type||Journal Article|
|Year of Publication||1996|
|Authors||Rosner H, Rubin L, Kestenbaum A|
|Journal||Clin J Pain|
|Date Published||1996 Mar|
|Keywords||Acetates, Adult, Aged, Amines, Analgesics, Cyclohexanecarboxylic Acids, Facial Pain, Female, gamma-Aminobutyric Acid, Herpesviridae Infections, HIV Infections, Humans, Intervertebral Disc Displacement, Male, Middle Aged, Neuralgia, Pain, Intractable, Peripheral Nervous System Diseases|
OBJECTIVE: This is a report of a trial of the new antiepileptic agent gabapentin in patients with intractable neuropathic pain.
DESIGN: A case series of patients with a diagnosis of neuropathic pain whose previous management was inadequate were given oral gabapentin in increasing doses and were followed for a minimum of 2 months, monitored for efficacy and side effects.
SETTING: An outpatient pain management center located within a major university medical center.
PATIENTS: Convenience sample of patients referred for management of intractable neuropathic pain.
INTERVENTIONS: Simplification of existing pharmacologic management, addition of gabapentin, and attempted reduction of opiate analgesic doses.
MAIN OUTCOME MEASURES: Patient self-reports and pain scores in successive office visits.
RESULTS: Gabapentin provides analgesic activity for patients with neuropathic pain and has the advantage of a low side effect profile and drug toxicity.
|Alternate Journal||Clin J Pain|